Le corticosurrénalome : progrès dans la physiopathologie et la prise en charge d’un cancer rare

Luton, 1990, Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy, N. Engl. J. Med., 322, 1195, 10.1056/NEJM199004263221705 Allolio, 2004, Management of adrenocortical carcinoma, Clin. Endocrinol. (Oxf), 60, 273, 10.1046/j.1365-2265.2003.01881.x Schteingart, 2005, Management of patients with adrenal cancer : recommendations of an international consensus conference, Endocr. Relat. Cancer, 12, 667, 10.1677/erc.1.01029 Libe, 2005, Molecular genetics of adrenocortical tumours, from familial to sporadic diseases, Eur. J. Endocrinol., 153, 477, 10.1530/eje.1.02004 Abiven, 2006, Clinical and biological features in the prognosis of adrenocortical cancer : poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients, J. Clin. Endocrinol. Metab., 91, 2650, 10.1210/jc.2005-2730 Wajchenberg, 2000, Adrenocortical carcinoma : clinical and laboratory observations, Cancer, 88, 711, 10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W Luton, 2000, Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center, Eur. J. Endocrinol., 143, 111, 10.1530/eje.0.1430111 Boland, 1998, Characterization of adrenal masses using unenhanced CT : an analysis of the literature, Am. J. Roentgenol, 171, 201, 10.2214/ajr.171.1.9648789 Becherer, 2001, FDG-PET in adrenocortical carcinoma, Cancer Biother Radiopharm., 16, 289, 10.1089/108497801753131363 Tenenbaum, 2004, 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours ? Preliminary results in 13 consecutive patients, Eur. J. Endocrinol., 150, 789, 10.1530/eje.0.1500789 Leboulleux, 2005, Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma : a prospective comparison with computed tomography, J. Clin. Endocrinol. Metab. Weiss, 1984, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors, Am. J. Surg. Pathol., 8, 163, 10.1097/00000478-198403000-00001 Gicquel, 2000, Pathogenesis of adrenocortical incidentalomas and genetic syndromes associated with adrenocortical neoplasms, Endocrinol. Metab. Clin. North Am., 29, 1, 10.1016/S0889-8529(05)70112-2 Gicquel, 2001, Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors, Cancer Res., 67, 6762 Mac Farlane, 1958, Cancer of the adrenal cortex : the natural history, prognosis and treatment in the study of 58 cases, Ann. Royal Coll. Surg., 109, 613 Icard, 2001, Adrenocortical carcinomas : surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group, World J. Surg., 25, 891, 10.1007/s00268-001-0047-y Assie, 2007, Prognostic parameters of metastatic adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 92, 148, 10.1210/jc.2006-0706 Bertherat, 2006, Mechanisms of disease : adrenocortical tumors-molecular advances and clinical perspectives, Nat. Clin. Pract. Endocrinol. Metab., 2, 632, 10.1038/ncpendmet0321 De Baere, 2006, Local treatment of adrenal cortical carcinoma metastases with interventional radiology techniques, Adrenal Cancer, 97 Berruti, 2005, Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma : a large prospective phase II trial, Endocr. Relat. Cancer, 12, 657, 10.1677/erc.1.01025 Van Slooten, 1984, The treatment of adrenocortical carcinoma with o,p-DDD : prognostic implications of serum level monitoring, Eur. J. Cancer Clin. Oncol., 20, 47, 10.1016/0277-5379(84)90033-6 Baudin, 2001, Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma, Cancer, 92, 1385, 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2 ????? De Fraipont, 2005, Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy, J. Clin. Endocrinol. Metab., 90, 1819, 10.1210/jc.2004-1075 Giordano, 2003, Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis, Am. J. Pathol., 162, 521, 10.1016/S0002-9440(10)63846-1 Kirschner, 2006, Emerging treatment strategies for adrenocortical carcinoma : a new hope, J. Clin. Endocrinol. Metab., 91, 14, 10.1210/jc.2005-1739 Tissier, 2005, Mutations of beta-catenin in adrenocortical tumors : activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors, Cancer Res., 65, 7622, 10.1158/0008-5472.CAN-05-0593 Terzolo, 2007, Adjuvant mitotane treatment for adrenocortical carcinoma, N. Engl. J. Med, 356, 2372, 10.1056/NEJMoa063360 Goldwasser, 2006, Chemotherapy for adrenal cortical cancer in Adrenal Cancer, 59 Bertherat, 2007, Adjuvant mitotane in adrenocortical carcinoma, N. Engl. J. Med., 357, 1256, 10.1056/NEJMc076267